ADial Pharmaceuticals is focused on developing novel and effective medications to treat addiction and addictive behaviors. In preliminary studies, our lead candidate, AD/TO:01, has shown promising results in reducing alcohol consumption; in fact, there are strong indications that AD/TO:01 is considerably more efficacious, with fewer side effects, than other alcohol treatments currently on the market. This compound is currently being evaluated in a double-blind, placebo-controlled, phase IIb NIH-sponsored human clinical trial. With the expectation of successful results, the plan is to launch phase III clinical trials in 2010, with an anticipated New Drug Application (NDA) in 2013.

ADial’s second and third compounds are in early-stage development, having completed pre-clinical testing. Both have demonstrated strong potential for both alcohol-related disorders and a number of currently under-treated addictive behaviors, such as substance abuse and food/obesity disorders. In addition to ADial’s pharmaceutical pipeline, it is also developing pharmacogenomic and alcohol sensitivity tests that will potentially aid clinicians in identifying and treating people who are genetically pre-disposed to alcohol-dependence.